| Depo-provera treatment does not abrogate protection from intravenous SIV challenge in female macaques immunized with an attenuated AIDS virus. | |
| | |
MedLine Citation:
|
PMID: 20352116 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: In a previous study, progesterone treatment of female monkeys immunized with live, attenuated SHIV89.6 abrogated the generally consistent protection from vaginal simian immunodeficiency virus (SIV) challenge. The mechanisms responsible for the loss of protection remain to be defined. The objective of the present study was to determine whether Depo-Provera administration alters protection from intravenous SIV challenge in SHIV-immunized female macaques. METHODS AND FINDINGS: Two groups of female macaques were immunized with attenuated SHIV89.6 and then challenged intravenously with SIVmac239. Four weeks before challenge, one animal group was treated with Depo-Provera, a commonly used injectable contraceptive progestin. As expected, SHIV-immunized monkeys had significantly lower peak and set-point plasma viral RNA levels compared to naïve controls, but in contrast to previously published findings with vaginal SIV challenge, the Depo-Provera SHIV-immunized animals controlled SIV replication to a similar, or even slightly greater, degree than did the untreated SHIV-immunized animals. Control of viral replication from week 4 to week 20 after challenge was more consistent in the progesterone-treated, SHIV-immunized animals than in untreated, SHIV-immunized animals. Although levels of interferon-gamma production were similar, the SIV-specific CD8(+) T cells of progesterone-treated animals expressed more functions than the anti-viral CD8(+) T cells from untreated animals. CONCLUSIONS: Depo-Provera did not diminish the control of viral replication after intravenous SIV challenge in female macaques immunized with a live-attenuated lentivirus. This result contrasts with the previously reported effect of Depo-Provera(R) on protection from vaginal SIV challenge and strongly implies that the decreased protection from vaginal challenge is due to effects of progesterone on the genital tract rather than to systemic effects. Further, these results demonstrate that the effects of hormonal contraceptives on vaccine efficacy need to be considered in the context of testing and use of an AIDS vaccine. |
| | |
Authors:
|
Meritxell Genescà; Michael B McChesney; Christopher J Miller |
Related Documents
:
|
15225296 - Analysis of ehrlichia ruminantium-specific t1/t2 responses during vaccination with a pr... 16616476 - The role of cd8 t cells in innate immunity and in antigen non-specific protection. 12911856 - Humoral and cell-mediated immune responses of d/d histocompatible pigs against classica... 20660136 - Ex vivo kinetics of early and long-term multifunctional human leukocyte antigen e-speci... 19154336 - Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of... 10790736 - Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-03-23 |
Journal Detail:
|
Title: PloS one Volume: 5 ISSN: 1932-6203 ISO Abbreviation: PLoS ONE Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-03-30 Completed Date: 2011-01-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101285081 Medline TA: PLoS One Country: United States |
Other Details:
|
Languages: eng Pagination: e9814 Citation Subset: IM |
Affiliation:
|
Center for Comparative Medicine, University of California Davis, Davis, California, United States of America. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Apoptosis CD4-Positive T-Lymphocytes / metabolism CD8-Positive T-Lymphocytes / metabolism Contraceptive Agents, Female / pharmacology Female Flow Cytometry / methods HIV / genetics* Leukocytes, Mononuclear / cytology Macaca Medroxyprogesterone Acetate / pharmacology* RNA, Viral / metabolism Simian immunodeficiency virus / metabolism* Transforming Growth Factor alpha / metabolism Transforming Growth Factor beta / metabolism Vaccines, Attenuated / immunology |
| Grant Support | |
ID/Acronym/Agency:
|
AI066314/AI/NIAID NIH HHS; AI44480/AI/NIAID NIH HHS; RR00169/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Contraceptive Agents, Female; 0/RNA, Viral; 0/Transforming Growth Factor alpha; 0/Transforming Growth Factor beta; 0/Vaccines, Attenuated; 71-58-9/Medroxyprogesterone Acetate |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Associations between total cerebral blood flow and age related changes of the brain.
Next Document: Identification of gp96 as a novel target for treatment of autoimmune disease in mice.